GlassScriptPhysician profile
Emily Geiser
NPI 1134731144
$6,015.94
in general payments reported to CMS, 2019-2025
41 companies · $2,978 in 2025
The $2,978 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.09 · 2023: $263 · 2024: $2,710 · 2025: $2,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,951.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $828.16 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $583.53 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $464.68 | 2024-2025 | Evenity, Prolia, Tepezza |
| Medtronic, INC. | $389.07 | 2024-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $276.78 | 2024-2025 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $276.30 | 2023-2025 | |
| Dexcom, INC. | $273.44 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $266.84 | 2022-2025 | Farxiga |
| Averitas Pharma INC. | $246.43 | 2024-2025 | Qutenza |
| Radius Health, INC. | $244.92 | 2024-2025 | Tymlos |
| Corcept Therapeutics | $213.36 | 2024-2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $203.94 | 2023-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $201.46 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $176.79 | 2025 | Twiist |
| Mannkind Corporation | $127.16 | 2023-2025 | Afrezza |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $112.89 | 2024-2025 | Yorvipath |
| Cequr Corporation | $108.32 | 2024-2025 | Cequr Simplicity |
| Insulet Corporation | $105.53 | 2024-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $98.14 | 2024-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.22 | 2024-2025 | Jardiance |
| Amphastar Pharmaceuticals, INC. | $86.21 | 2024-2025 | |
| Abbvie INC. | $65.48 | 2025 | |
| Currax Pharmaceuticals LLC | $59.72 | 2023-2025 | Contrave, Nexlizet, Nexletol |
| Verity Pharmaceuticals INC. | $56.00 | 2024 | Tlando |
| Xeris Pharmaceuticals, INC. | $47.90 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $45.88 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $39.04 | 2025 | |
| Tolmar, INC. | $33.30 | 2024-2025 | Jatenzo |
| Ascensia Diabetes Care US INC. | $30.58 | 2024 | |
| Embecta Corp. | $30.36 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Ultragenyx Pharmaceutical INC. | $27.74 | 2023 | |
| Chiesi USA, INC. | $27.60 | 2024 | Mycapssa |
| Glaxosmithkline, LLC. | $27.27 | 2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $25.10 | 2025 | Inspire |
| Vivus LLC | $23.56 | 2024 | Qsymia |
| Globus Medical, INC. | $18.87 | 2025 | Senza |
| Alvogen INC | $18.59 | 2024 | Teriparatide |
| Madrigal Pharmaceuticals | $17.82 | 2025 | Rezdiffra |
| Almatica Pharma LLC | $17.19 | 2025 | Teriparatide |
| Amryt Pharma Holdings LTD | $17.12 | 2023 | Myalept |
| Evoke Pharma, INC. | $16.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Geiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.